BACKGROUND AND PURPOSE: The GPCR Epstein-Barr virus-induced gene 2 (EBI2, also known as GPR183) is activated by oxysterols and plays a pivotal role in the regulation of B cell migration during immune responses. While the molecular basis of agonist binding has been addressed in several studies, the concept of biased agonism of the EBI2 receptor has not been explored. EXPERIMENTAL APPROACH: We investigated the effects of the EBI2 endogenous agonist 7α,25-dihydroxycholesterol (7α,25-OHC) on G protein-dependent and -independent pathways as well as sodium ion allosterism using site-directed mutagenesis and functional studies. Moreover, we generated a homology model of the EBI2 receptor to investigate the structural basis of the allosteric modulation by sodium. KEY RESULTS: Residue N114, located in the middle of transmembrane-III at position III:11/3.35, was found to function as an efficacy switch. Thus, substituting N114 with an alanine (N114A) completely abolished heterotrimeric G protein subunit Gi α activation by 7α,25-OHC even though the specific binding of [3 H]-7α,25-OHC increased. In contrast, the N114A mutant was still able to recruit β-arrestin and even had an enhanced potency (18.7-fold) compared with EBI2 wild type. Sodium had a negative allosteric effect on oxysterol binding that was mediated via N114, verifying the key role of N114. This was further supported by molecular modelling of the ion binding site based on a EBI2 receptor homology model. CONCLUSIONS AND IMPLICATIONS: Collectively, our data point to N114 as a key residue for EBI2 signalling controlling the balance between G protein-dependent and -independent pathways and facilitating sodium binding.
BACKGROUND AND PURPOSE: The GPCR Epstein-Barr virus-induced gene 2 (EBI2, also known as GPR183) is activated by oxysterols and plays a pivotal role in the regulation of B cell migration during immune responses. While the molecular basis of agonist binding has been addressed in several studies, the concept of biased agonism of the EBI2 receptor has not been explored. EXPERIMENTAL APPROACH: We investigated the effects of the EBI2 endogenous agonist 7α,25-dihydroxycholesterol (7α,25-OHC) on G protein-dependent and -independent pathways as well as sodium ion allosterism using site-directed mutagenesis and functional studies. Moreover, we generated a homology model of the EBI2 receptor to investigate the structural basis of the allosteric modulation by sodium. KEY RESULTS: Residue N114, located in the middle of transmembrane-III at position III:11/3.35, was found to function as an efficacy switch. Thus, substituting N114 with an alanine (N114A) completely abolished heterotrimeric G protein subunit Gi α activation by 7α,25-OHC even though the specific binding of [3 H]-7α,25-OHC increased. In contrast, the N114A mutant was still able to recruit β-arrestin and even had an enhanced potency (18.7-fold) compared with EBI2 wild type. Sodium had a negative allosteric effect on oxysterol binding that was mediated via N114, verifying the key role of N114. This was further supported by molecular modelling of the ion binding site based on a EBI2 receptor homology model. CONCLUSIONS AND IMPLICATIONS: Collectively, our data point to N114 as a key residue for EBI2 signalling controlling the balance between G protein-dependent and -independent pathways and facilitating sodium binding.
Authors: Mette M Rosenkilde; Tau Benned-Jensen; Thomas M Frimurer; Thue W Schwartz Journal: Trends Pharmacol Sci Date: 2010-09-25 Impact factor: 14.819
Authors: Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath Journal: Br J Pharmacol Date: 2015-07 Impact factor: 8.739
Authors: Viktorija Daugvilaite; Christian Medom Madsen; Michael Lückmann; Clara Castello Echeverria; Andreas Walter Sailer; Thomas Michael Frimurer; Mette Marie Rosenkilde; Tau Benned-Jensen Journal: Br J Pharmacol Date: 2017-05-04 Impact factor: 8.739
Authors: Viktorija Daugvilaite; Christian Medom Madsen; Michael Lückmann; Clara Castello Echeverria; Andreas Walter Sailer; Thomas Michael Frimurer; Mette Marie Rosenkilde; Tau Benned-Jensen Journal: Br J Pharmacol Date: 2017-05-04 Impact factor: 8.739
Authors: Timothy F Miles; Katja Spiess; Kevin M Jude; Naotaka Tsutsumi; John S Burg; Jessica R Ingram; Deepa Waghray; Gertrud M Hjorto; Olav Larsen; Hidde L Ploegh; Mette M Rosenkilde; K Christopher Garcia Journal: Elife Date: 2018-06-08 Impact factor: 8.140
Authors: Astrid S Jørgensen; Olav Larsen; Edith Uetz-von Allmen; Michael Lückmann; Daniel F Legler; Thomas M Frimurer; Christopher T Veldkamp; Gertrud M Hjortø; Mette M Rosenkilde Journal: Front Immunol Date: 2019-09-13 Impact factor: 7.561
Authors: Katja Spiess; Sofie O Bagger; Lola J Torz; Kristian H R Jensen; Anna L Walser; Jone M Kvam; Ann-Sofie K Møgelmose; Viktorija Daugvilaite; Riia K Junnila; Gertrud M Hjortø; Mette M Rosenkilde Journal: Ann N Y Acad Sci Date: 2019-10-29 Impact factor: 5.691